Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER: Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma
NCT03526679Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, eribulin in liposarcoma (LPS), leiomyosarcoma (LMS), sponsored by National Taiwan University Hospital. Started Jul 2018; status: completed.
02
Drugs
lenvatiniberibulin
03
Conditions
liposarcoma (LPS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03526679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526679.